There is considerable evidence based on experimental pathology that heparin/heparinoids will benefit the course of the various forms of human proliferative nephritis. An alternative to heparin may be pentosan polysulphate. Another possibility is the infusion of prostaglandin E1 because of its anti-inflammatory and potentially antiproliferative actions. Both these approaches mimic natural pathophysiological control mechanisms.
CameronJSHow can we treat glomerulonephritis?Nephrol Dial Transplant1990; 5 (suppl 1): 16–22.
2.
RemuzziGBertoniTIs glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?Kidney Int1990; 38: 384–394.
3.
WardleENCells and mediators in glomerulonephritis. Nephron1988; 49: 265–276.
4.
WardleENCytokine growth factors and glomerulonephritis. Nephron1991; 57: 257–261.
5.
PatronoCPierucciAThe use of antiplatelet agents in glomerulonephritis: a pharmacological approach. Nephrol Dial Tranplant1990; 5 (suppl 1): 29–32.
6.
SalvatiPFertiCFerrarioRG Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney Int1990; 38: 447–458.
7.
SilfverskioldBPHeparin and experimental glomerulonephritis. Scand Arch Physiol1940; 83: 175–179.
8.
KleinermanJEffects of heparin on experimental nephritis in rabbits. Lab Invest1954; 3: 495–500.
9.
GoodRAThomasLStudies on the generalized Shwartzman reaction. IV. Prevention of the local and generalized Shwartzman reactions with heparin. J Exp Med1953; 97: 871–878.
10.
KazatchkineMDFearonDTSilbertJESurface associated heparin inhibits zymosan induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins. J Exp Med1979; 150: 1202–1215.
11.
BrestelEPKroesMTHeparin inhibits the ‘quasi-lipoxygenase’ activity of haemoglobin toward linoleic acid by oxidant scavenging. Prostaglandins, Leukotrienes, Essent Fatty Acids1989; 36: 21–24.
12.
HiebertLMLiuJMHeparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis1990; 83: 47–51.
13.
GrantDLongWFWilliamsonFBPericellular heparins contribute to the protection of cells from free radicals. Med Hypotheses1987; 23: 67–72.
14.
KarlssonJMarklundLHeparin induced release of extracellular superoxide dismutase to human blood plasma. Biochem J1987; 242: 55–59.
15.
CarrJThe anti-inflammatory action of heparin: heparin as an antagonist to histamine, bradykinin and prostaglandin E. Thromb Res1979; 16: 507–511.
16.
HalpernEMilliezPLagrueGProtective action of heparin on experimental immune nephritis. Nature1965; 205: 257–259.
17.
CastellotJHooverRLHarperRAHeparin and glomerular epithelial cell secreted heparin like species inhibit mesangial cell proliferation. Am J Pathol1985; 120: 427–434.
18.
KjellenLLindahlUProteoglycans: structures and interactions. Ann Rev Biochem1991; 60: 443–475.
19.
RuoslahtiEYamaguchiYProteoglycans as modulators of growth activities. Cell1991; 64: 867–869.
20.
KleinDJBrownDMKimYProteoglycans synthesized by human mesangial cells in culture. J Biol Chem1990; 265: 9533–9534.
21.
GroggelGCMarinedesGMHovingePInhibition of rat mesangial cell growth by heparan sulphate. Am J Physiol1990; 258: F259–F265.
22.
GroggelGCHovingePLinkerAProteoglycan and glycosaminoglycan synthesis by cultured rat mesangial cells. J Cell Physiol1991; 147: 455–459.
23.
JacksonRLBuschSJCardinADGlycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev1991; 71: 481–539.
24.
SmithCDWenDMooberrySLInhibition of PI 4 phosphate kinase by heparin: a possible mechanism for the antiproliferative effects of heparin. Biochem J1992; 281: 803–808.
25.
ReillyCFKindyMSBrownKE Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem1989; 264: 6990–6995.
26.
ZaragosaRBattle-TraceyKMOwenNEHeparin inhibits sodium – hydrogen ion exchange in vascular smooth muscle cells. Am J Physiol1990; 258: C46–C53.
27.
WrightTCPukacLACastellotJJ Heparin suppresses the induction of c-fos and c-myc RNA in murine fibroblasts by selective inhibition of a protein kinase C dependent pathway. Proc Natl Acad Sci USA1989; 86: 3199–3205.
28.
HerbertJMMaffrandJPEffect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity. Biochim Biophys Acta1991; 1091: 432–441.
29.
WardleENCell biology and glomerulonephritis. Nephron1991; 59: 529–532.
30.
WardleENPlatelet factors, diabetes and vascular diseases. Saudi Med J1989; 10: 83–88.
31.
RosenbergRDBiochemistry of heparin – antithrombin interactions. Am J Med1989; 87 (suppl 3B): 2S–9S.
32.
LindbladBWrightSWBurkelWE Endothelial cell proliferation in vitro after incubation with anticonvulsant and antiplatelet drugs. Artery1988; 16: 15–24.
33.
ImamuraTMitsuiYHeparan sulphate and heparin as a potentiator or suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res1987; 172: 92–100.
34.
ClowesAWKarnovskyMJSuppression by heparin of smooth muscle cell proliferation in injured arteries. Nature1977; 265: 625–627.
35.
WrightTCCastellotJJDiamondJRRegulation of cellular proliferation by heparin and heparan sulphate. In: Heparin (LaneDALindahlU eds). London: Edward Arnold, 1989; pp 295–316.
36.
HiebertLMLiuJThe protective action of polyelectrolytes on endothelium. Semin Thromb Haemost1991; 17 (suppl 1): 42–46.
37.
JonesAGeczyCLThrombin and factor Xa enhance the production of interleukin 1. Immunology1990; 71: 236–241.
38.
SaitoTWolfAMenonNKLysolecithins as endothelium dependent vascular smooth muscle relaxants that differ from nitric oxide. Proc Natl Acad Sci USA1988; 85: 8246–8250.
39.
RauchALBuckalewRMLysophospholipids are natriuretic and diuretic in rats. Am J Physiol1988; 254: F824–F827.
40.
Ferrer-LopezPRenestoPPrevostMCHeparin inhibits neutrophil induced platelet activation via cathepsin G. J Lab Clin Med1992; 119: 231–239.
41.
EkreHPTInhibition of human and guinea pig complement by heparin fractions differing in affinity for anti-thrombin III. Int J Pharmacol1985; 7: 271–280.
42.
LeungLSaigoKGrantDHeparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Blood1989; 73: 177–184.
43.
CzarnetzkiBMPanneckWFroschPJInhibitory effect of heparin on leukocyte chemotactic factors. Clin Exp Immunol1980; 39: 526–531.
44.
MatznerYMarxGDrexterRInhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost1984; 52: 134–137.
45.
MavierPPreauxAMRosenbaumJToxicity of polymorphonuclear neutrophils against hepatocytes: protective effect of heparin. Biochem Pharmacol1989; 38: 1865–1867.
46.
WalshRLDillonTJScicchitanoRHeparin and heparan sulphate are inhibitors of human leucocyte elastase. Clin Sci1991; 81: 341–346.
47.
ParishCRSnowedenJMLymphocytes express a diverse array of specific receptors for sulfated polysaccharides. Cell Immunol1985; 91: 201–205.
48.
SchwartingGAGajewskiAHeparin inhibits specific glycosyl-transferase activities on interleukin 2 activated murine T cells. Biosci Rep1988; 8: 389–399.
49.
FrieriMMetcalfeDD Analysis of the effect of mast cell granules on lymphocyte blastogenesis.J Immunol1983; 131: 1942–1949.
50.
KimuraKMatsubaraJSogohSRole of glycosaminoglycans in the regulation of T cell proliferation. J Immunol1991; 146: 2618–2624.
51.
WrenshallLECerraFBCarlsonA Regulation of murine splenocyte responses by heparan sulfate.J Immunol1991; 147: 455–459.
52.
GhoshTKEisPSMullaneyJMCompetitive, reversible and potent antagonism of inositol 1,4,5-triphosphate activated calcium release by heparin. J Biol Chem1988; 263: 11075–11079.
53.
LiderOBaharauEMekariYASuppression of experimental auto-immune disease and prolongation of allograft survival by treatment of animals with low doses of heparin. J Clin Invest1989; 83: 752–756.
54.
Bal-NerMEldorAWassermanLInhibition of heparanse mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin. Blood1987; 70: 551–527.
55.
SaiPPoguSOvaryM Heparin attenuates low dose streptozotocin induced immune diabetes in mice and inhibits the beta-cell binding of T splenocytes in vitro. Diabetologia1991; 24: 212–217.
56.
NaparsteckYBen-YehudaAMadoioMPBinding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL – lpr/lpr mice by heparin. Arthritis Rheum1990; 33: 1554–1559.
57.
WarldeENUldallPThe effects of heparin in patients with accelerated hypertension, progressive nephritis and renal allografts. Br Med J1972; iv: 135–139.
58.
MajoorCLHSchlatmanRJansenAPExcretion pattern and mechanism of diuresis by heparin. Clin Chim Acta1960; 5: 591–606.
59.
IchikawaIYoshidaYFugoAEffect of heparin on the glomerular structure and function of remnant nephrons. Kidney Int1988; 34: 638–644.
60.
DonadioJVAndersonCFMitchellJCMembranoproliferative glomerulonephritis: a prospective trial of platelet inhibitor therapy. New Engl J Med1984; 310: 1421–1426.
61.
LinesDRFocal glomerulosclerosis treated with heparin. Arch Dis Child1989; 64: 855–857.
62.
PerssonENordenstrmJNilsson-EhlePLipolytic and anticoagulant activities of low molecular weight fragment of heparin. Eur J Clin Invest1985; 15: 215–220.
63.
CadroyYHorbettTAHansonSRInhibition of platelet dependent thrombosis by low molecular weight heparin (CY222) in comparison with standard heparin. J Lab Clin Med1989; 114: 349–357.
64.
JaquesLBHiebertLMWiceSMEvidence from endothelium of gastric absorption of heparin and of dextran sulfate 8000. J Lab Clin Med1991; 117: 122–130.
65.
VasdevSPrabhakaranVSampsonCAHeparin lowers blood pressure and vascular calcium uptake in hypertensive rats. Scand J Clin Lab Invest1991; 51: 321–328.
66.
BagchursWMJeuninkMFElemaJD Effects of platelets and heparin on rat mesangial cell proliferation in vivo [Abstract]. Kidney Int1989; 36: 510.
67.
HedbomEHeinegardDInteraction of a 59 kDa connective tissue matrix protein with collagen type I and collagen type II. J Biol Chem1989; 264: 6898–6905.
68.
YamaguchiYMannDMRuoslahtiENegative regulation of transforming growth factor beta by the proteoglycan decorin. Nature1990; 346: 281–284.
69.
BorderWAOkudaSLanguinoLRTransforming growth factor beta regulates production of proteoglycans by mesangial cells. Kidney Int1990; 37: 689–695.
70.
NakamuraTEbihoraIShiratoIModulation of basement membrane component gene expression in glomeruli of aminonucleoside nephrosis. Lab Invest1991; 64: 640–647.
71.
ScullyMFKakkarVVEffect of a pentosan polysulphate upon thrombin and factor Xa inactivation by anti-thrombin III. Biochem J1984; 222: 571–578.
72.
FreyburgerGLarrueFMancietGHaemorheological changes in elderly subjects: effect of pentosan polysulphate and possible role of leucocyte arachidonic acid metabolism. Thromb Haemost1987; 57: 322–325.
73.
BarrowcliffeTEGrayEMertonREAnticoagulant activities of pentosan polysulphate and release of hepatic triglyceride lipase. Thromb Haemost1986; 56: 202–206.
74.
KrupinskiKBreddinHKCasuBAnticoagulant and antithrombotic effects of chemically modified heparins and pentosan polysulphate. Haemostasis1990; 20: 81–92.
75.
HirshJRationale for development of low molecular weight heparins. Am J Surg1991; 161: 512–518.
76.
BerthouxFCFreyriaAMZechPYActivité anti-complémentaire d'un polyanion: le polyester sulfurique de pentosane. Pathol Biol1977; 25: 33–36.
77.
MocharlaRMocharlaHWheyRPolyanions block murine macrophage Fc receptor mediated antibody dependent cell cytotoxicity and binding. Immunol Invest1989; 18: 689–696.
78.
BaiciASalgamPFehrKInhibition of human elastase released from polymorphonuclear leucocytes by gold sodium thiomalate and pentosan polysulphate. Biochem Pharmacol1981; 30: 703–708.
79.
DelvosUPaulJEMller-BerghausGEffects of the heparinoid pentosan polysulphate (SP 54) on the functional properties of cultured bovine aortic endothelial cells. Blut1985; 51: 127–136.
80.
HerbertJMFlotardDPaulREffect of pentosan polysulphate on endothelial regeneration. Pathol Biol1989; 37: 847–850.
81.
HerbertJMNutiDPaulRIn vitro and ex vivo regulation of vascular smooth muscle cell growth and phenotypic modulation by sulphated polysaccharides. Artery1988; 16: 1–14.
82.
McCarthyKJAccavittiMACouchmanJRDistribution of glycosaminoglycans in the glomerular basement membrane and mesangial matrix. J Cell Biol1989; 109: 3187–3198.
83.
TateGMandellBFSchumacherHR Suppression of acute inflammation by 15-methylprostaglandin E1. Lab Invest1988; 59: 192–199.
84.
GoldyneMEEicosanoids and immunoregulation. In: Recent Advances in Clinical Immunology (ThompsonRARoseNR eds). London: Churchill Livingstone1983: pp 9–36.
85.
KunkelSLChensueSWProstaglandins and the regulation of immune responses. Adv lnflamm Res1984; 7: 93–102.
86.
SpenglerRNSpenglerMLStrieterRMModulation of TNF alpha gene expression. J Immunol1989; 142: 4346–4350.
87.
BittermanPBWeuversMDRennardSIModulation of alveolar macrophage driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest1986; 77: 700–708.
88.
KelleyVEWinklesteinAIzuiS Prostaglandin E1 inhibits T-cell proliferation and renal disease in MRL/1 mice. Clin Immunol Immunopathol1981; 21: 190–203.
89.
McLeishKRGoharaAFGunningWTSuppression of antibody synthesis by prostaglandin E as a mechanism for preventing immune complex nephritis. Lab Invest 1982; 47: 147–152.
90.
IzuiSKelleyVEMcConaheyA Selective suppression of retroviral glycoprotein 70 or anti-gp 70 immune complex formation by prostaglandin E1 in murine systemic lupus erythyematosus. J Exp Med1981; 152: 1645–1658.
91.
KunkelSLZanetteMSapinC Suppression of nephrotoxic serum nephritis in rats by prostaglandin E1Am J Pathol1982; 108: 240–245.
92.
HinglaisHPelletierLMVialMC Effect of prostaglandin E1 in Brown Norway rats with mercury induced auto-immune disease. Clin Immunol Immunopathol1986; 40: 401–409.
93.
YoshikawaMSuzukiHKatoH Effects of prostaglandin E1 on collagen diseases with high levels of circulating immune complexes. J Rheumatol1990; 17: 1513–1514.
94.
NagayamaYNamuraYTamuraT Beneficial effect of prostaglandin E1 in three cases of lupus nephritis with nephrotic syndrome. Ann Allergy1988; 61: 289–295.
95.
LinCY Improvement in steroid and immunosuppressive drug resistant lupus nephritis by intravenous prostaglandin E1 therapy. Nephron1990; 55: 258–264.
